News Reader.info

ABSTRACT Defects in DNA mismatch repair (MMR) are associated with a predisposition to tumorigenesis and with drug resistance owing to high mutation rates and failure to engage

DNA-damage-induced apoptosis. DNA minor groove binders (MGBs) are a class of anticancer agents highly effective in a variety of human cancers. Owing to their mode of action, DNA MGB-induced

DNA damage may be a substrate for DNA MMR. This study was aimed at investigating the effect of loss of MMR on the sensitivity to brostallicin (PNU-166196), a novel synthetic

_α_-bromoacrylic, second-generation DNA MGB currently in Phase II clinical trials and structurally related to distamycin A. Brostallicin activity was compared to a benzoyl mustard derivative

of distamycin A (tallimustine). We report that the sensitivities of MLH1-deficient and -proficient HCT116 human colon carcinoma cells were comparable after treatment with brostallicin,

while tallimustine resulted in a three times lower cytotoxicity in MLH1-deficient than in -proficient cells. MSH2-deficient HEC59 parental endometrial adenocarcinoma cells were as sensitive

as the proficient HEC59+ch2 cells after brostallicin treatment, but were 1.8-fold resistant after tallimustine treatment as compared to the MSH2-proficient HEC59+ch2 counterpart. In

addition, p53-deficient mouse fibroblasts lacking PMS2 were as sensitive to brostallicin as PMS2-proficient cells, but were 1.6-fold resistant to tallimustine. Loss of neither ATM nor DNA-PK

affected sensitivity to brostallicin in p53-deficient mouse embryonic fibroblasts, indicating that brostallicin-induced cytotoxicity in a p53-deficient genetic background does not seem to

require these kinases. These data show that, unlike other DNA MGBs, MMR-deficient cells retain their sensitivity to this new _α_-bromoacrylic derivative, indicating that brostallicin-induced

cytotoxicity does not depend on functional DNA MMR. Since DNA MMR deficiency is common in numerous types of tumours, brostallicin potentially offers the advantage of being effective against

MMR-defective tumours that are refractory to several anticancer agents. SIMILAR CONTENT BEING VIEWED BY OTHERS MOLECULAR DISRUPTION OF DNA POLYMERASE Β FOR PLATINUM SENSITISATION AND

SYNTHETIC LETHALITY IN EPITHELIAL OVARIAN CANCERS Article Open access 05 March 2021 ALTERNATE THERAPEUTIC PATHWAYS FOR PARP INHIBITORS AND POTENTIAL MECHANISMS OF RESISTANCE Article Open

access 25 January 2021 IN SILICO SCREENING IDENTIFIES A NOVEL SMALL MOLECULE INHIBITOR THAT COUNTERACTS PARP INHIBITOR RESISTANCE IN OVARIAN CANCER Article Open access 13 April 2021 MAIN

Minor groove binders (MGBs) represent an interesting class of anticancer agents, which have been shown to be highly effective in _in vitro_ and _in vivo_ preclinical tumour models

unresponsive to other antineoplastic agents (Martin et al, 1981; Li et al, 1982, 1992; Hartley et al, 1988; D'Alessio et al, 1994; D'Incalci, 1994; Colella et al, 1999; Marchini et

al, 1999; Geroni et al, 2002). The main representatives of this class, which reached the clinic, are the antitumour agents derived from CC-1065, that is, adozelesin, carzelesin, and

bizelesin, and the distamycin A derivative tallimustine. These ‘classical’ MGBs have been shown to be highly DNA sequence-specific (Lee et al, 1993; D'Incalci, 1994) and to exert their

cytotoxic effect through the ability to _per se_ directly alkylate DNA mainly at the N3 position of adenines exposed in (TA)-rich sequences in the DNA minor groove (Hurley et al, 1984;

Reynolds et al, 1985; Broggini et al, 1995, 1991; Sun and Hurley, 1992; D'Incalci, 1994; Marchini et al, 1998), without the requirement to be activated by other pathways (e.g.,

enzymatic activation of the drug). The absence of significant antitumour activity for nonalkylating MGBs (Marchini et al, 1998) indicates that the N3 alkylation activity of these compounds

is a prerequisite for their cytotoxicity. MGBs activity, however, has previously been reported (Colella et al, 1999) to be associated with reduced susceptibility to the cytotoxic effect in

tumour cells with defects in DNA mismatch repair (MMR), similar to certain chemicals, including MNNG, which alkylates O6 of guanines, and anticancer agents such as doxorubicin and cisplatin

(Branch et al, 1995; Drummond et al, 1996). MMR proteins recognise mismatched base pairs in the DNA, arising either spontaneously during DNA metabolism or from modified nucleotides provoked

by physical and chemical agents, and are thought to link DNA damage recognition to an apoptotic pathway, thereby preventing mutagenesis, tumorigenesis, and tumour progression (Modrich, 1991;

Fink et al, 1998). Tumours resulting from MMR-deficiency include the hereditary nonpolyposis colon cancer (HNPCC) and some sporadic carcinomas such as mammary, ovarian, or endometrial

cancers (Peltomaki, 2001). The development of novel MGBs able to overcome the involvement of MMR assumes great clinical importance with respect to the treatment of tumours deficient in MMR.

A novel _α_-bromoacryloyl derivative of distamycin A, PNU-151807, which exhibits no alkylating activity _per se_, has been identified (Marchini et al, 1999). The cytotoxic effect has been

shown to not depend on MLH1 in some tumour cells (Colella et al, 1999) and has been attributed to the _α_-bromoacrylic moiety of the compound, which seems to interfere with cell cycle

progression via yet unknown pathways (Cozzi, 2000; Geroni et al, 2002). Recently, brostallicin (PNU-166196), a synthetic _α_-bromoacrylic MGB structurally related to PNU-151807, has been

selected for clinical development. Brostallicin has shown very promising activity in experimental tumour models; its _in vitro_ and _in vivo_ activity is increased in tumour cells with

higher glutathione (GSH) and/or glutathione-_S_-transferase (GST) levels (Geroni et al, 2002). The _α_-bromoacrylic moiety of brostallicin was found to react with GSH, in a reaction

catalysed by GST, with the possible formation of a highly reactive GSH-complex able to bind covalently to DNA (Geroni et al, 2002; Cozzi, 2003). The present study was aimed at investigating

the effect of loss of MMR on the sensitivity to brostallicin compared to the structurally related tallimustine, using cell lines deficient or proficient in MLH1, MSH2, or PMS2, respectively.

A putative involvement of two members of the PI3-like kinase family, ATM and DNA-PK, which link DNA damage and cell cycle response in drug-induced cytotoxicity, was also investigated. We

report that MMR-deficient cells retain sensitivity to brostallicin, thereby extending the list of potential anticancer agents for use in the treatment of MMR-deficient tumours, and that

brostallicin-induced cytotoxicity may not require ATM and DNA-PK. MATERIALS AND METHODS CELL LINES The MLH1-deficient human colorectal adenocarcinoma cell line HCT116 was obtained from the

American Type Culture Collection (ATCC CCL 247), and a subline complemented with chromosome 3 carrying the wild-type gene for _hMLH1_ (clone HCT116/3–6, identified here as HCT116+ch3) was

obtained from Dr M Koi (Koi et al, 1994) as were the MSH2-deficient human endometrial adenocarcinoma cell line HEC59 (Umar et al, 1997) and a subline complemented with chromosome 2 carrying

the wild-type gene for _hMSH2_ (clone HEC59/2–4, identified here as HEC59+ch2). HCT116 cells contain a hemizygous mutation in _MLH1_ resulting in a truncated, nonfunctional protein (Boyer et

al, 1995). Similarly, the HEC59 cells are mutated at different loci on both alleles of _MSH2_ and are deficient in repair activity (Umar et al, 1997). The chromosome-complemented sublines

HCT116+ch3 and HEC59+ch2 are competent in DNA MMR. HCT116 and HEC59 cell lines were maintained in Iscove's modified Dulbecco's medium (Life Technologies, Basel, Switzerland)

supplemented with 2 mM L-glutamine and 10% heat-inactivated foetal bovine serum (Oxoid, Basel, Switzerland). The chromosome-complemented lines were maintained in a medium supplemented with

geneticin (400 _μ_g ml−1 for HCT116+ch3, and 600 _μ_g ml−1 for HEC59+ch2) (Life Technologies). Although the extent of possible effects of the introduction of an extra chromosome are not

fully clear, it is generally acknowledged that it does not spoil the effects of loss of MMR on drug sensitivity. PMS2−/−/p53−/− and PMS2+/+/p53−/− cell lines, established from

E1A/Ha-Ras-transformed knockout mice primary fibroblasts, were generously provided by Dr P Glazer (Zeng et al, 2000). Cells are maintained in culture for a limited number of passages and are

routinely tested for the expression of MMR proteins. The ATM+/+/p53−/− and ATM−/−/p53−/−, and the DNA-PK+/+/p53−/− and DNA-PK−/−/p53−/− mouse embryonic fibroblasts, were generously provided

by Dr P Leder (Westphal et al, 1997) and Dr EH Goodwin (Bailey et al, 1999), respectively. The cells were maintained in DMEM medium supplemented with 2 mM L-glutamine (Life Technologies),

10% heat-inactivated foetal calf serum (Oxoid) and penicillin/streptomycin (100 U ml−1/100 _μ_g ml−1, Life Technologies). All cell lines were tested negative for contamination with

_Mycoplasma_ spp. and maintained in a controlled environment of 5% CO2 and 95% relative humidity at 37°C. Except for the ATM+/+/p53−/− and ATM−/−/p53−/− mouse cells, which grow as a

monolayer and do not form colonies, all other cell lines used in these experiments form well-defined individual colonies when seeded sparsely on standard tissue culture plates. REAGENTS

Distamycin A and its derivatives brostallicin (PNU-166196) and tallimustine (PNU-152241) were synthesised by Pharmacia Italy (Nerviano, Italy). The chemical structures of the derivatives are

presented in Figure 1. Brostallicin was dissolved in methanol, tallimustine in DMSO, and distamycin A in water. Stock solutions were stored at −20°C. The final concentration of DMSO or

methanol in the cultures was <0.1% at all drug concentrations and in controls. Previous experiments (data not shown) have shown that neither 0.1% DMSO nor 0.1% methanol affects the

viability or growth of these cell lines. MPE FOOTPRINTING ANALYSIS The MPE footprinting method has been previously described in detail (Hertzberg and Dervan, 1984). The 4492- and 751-bp

fragments of SV40-labelled plasmid previously described (Marchini et al, 1999) were incubated with distamycin A, tallimustine, and brostalicin (50 _μ_ M) for 1 h at room temperature and

treated for 30 min at room temperature with a solution of MPE-(NH4)2-Fe(SO4)2 (synthesised by Pharmacia, Italy, according to the published method; Hertzberg and Dervan, 1984). After

precipitation, DNA was resuspended in loading buffer and electrophoresed on an 8% polyacrylamide 7 M urea gel and autoradiographed. TAQ POLYMERASE STOP ASSAY Studies with the Taq stop assay

were based on a previously reported method (Ponti et al, 1991). Prior to drug-DNA incubation, plasmid pBSSK-TOPO II was linearised with a _Pst_I restriction enzyme (NEB) to provide a stop

for the Taq polymerase, downstream from the primer. After drug treatment, the DNA was precipitated and washed as described (Ponti et al, 1991). The primer was 5′-end labelled with T4

polynucleotide kinase (NEB) and [_γ_-32P] ATP (5000 Ci mmol−1, Amersham). The synthetic primer sequence and the linear PCR amplification conditions were performed as described (Marchini et

al, 1998). Samples were then purified by extraction with an equal volume of chloroform–isoamyl alcohol (24 : 1), and then precipitated and washed following the standard protocol. Dried

samples were resuspended in loading buffer and denatured at 90°C for 2 min before loading onto an 8% polyacrylamide denatured gel. After the run, the gel was dried and autoradiographed.

CLONOGENIC SURVIVAL AND MTT PROLIFERATION ASSAYS Clonogenic survival in response to drug treatment was performed by plating 250 cells in 60 mm cell culture dishes. After 24 h, the drug was

added, followed by incubation in a drug-containing medium for 2 h or 24 h and then in a drug-free medium for another 6–8 days at 37°C in a humidified atmosphere containing 5% carbon dioxide.

Cells were then fixed with 25% acetic acid in ethanol and stained with Giemsa. Colonies of at least 50 cells were scored visually. Each experiment was performed a minimum of three times

using triplicate cultures for each drug concentration. The logarithm of relative colony formation was plotted against the concentration of the drug. The IC50 was estimated by linear

interpolation of the logarithmic transformed relative plating efficiencies. For ATM+/+/p53−/− and ATM−/−/p53−/− mouse cells that do not form distinct colonies, the drug sensitivity was

determined by the MTT assay (Mosmann, 1983). MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazoliumbromide) measures the mitochondrial dehydrogenase of surviving cells. Cells growing

in the log phase were harvested by brief trypsinisation. A total of 1000 cells were plated (96 well plates) 24 h prior to 2 h drug treatment. Cells were then grown in a drug-free medium for

another 4 days at 37°C in a humidified atmosphere containing 5% carbon dioxide. A volume of 20 _μ_l MTT in PBS to a final concentration of 0.5 mg ml−1 was added, followed by incubation at

37°C for 4 h, aspiration of the medium, and addition of 200 _μ_l DMSO. The optical density was measured by the _E_max microplate reader E9336 (Molecular Devices, Clearwater, MN, USA) at 540 

nm, setting the value of the cell lines in the medium to 1.0 (control) and the value of the no cells blank to zero. Differences in drug sensitivity of the respective cell lines were

determined from at least four independent experiments and are reported as the concentration required to suppress proliferation by 50% (IC50). STATISTICAL ANALYSIS The mean±s.d. values were

calculated for all data sets. The two-sided paired _t_-test was used to compare the effects on drug sensitivity. _P_<0.05 was considered to be statistically significant. RESULTS

BROSTALLICIN DOES NOT ALKYLATE DNA _PER SE_ BUT THROUGH THE INTERACTION WITH GSH/GST Noncovalent interactions of brostallicin and tallimustine (TAM) with DNA were compared to those of

distamycin A (DISTA). The data reported in Figure 2 show an autoradiograph of a classical ladder of an MPE-footprinting experiment tested on the 751-bp (panel A) and 4492-bp fragments (panel

B) of the SV40 DNA plasmid. Each band corresponds to a DNA fragment differing in size by a single nucleotide. When a DNA region is protected by the presence of a molecule, chemical

digestion is blocked and a ‘gap’ is present on the autoradiograph. In the control (CTR, Figure 2), all fragments are present with broadly the same signal intensity on the gel, while in all

the treated sample lanes a typical ‘gap’ is common in AT-rich regions. The brackets highlight these regions. The distamycin A backbone present in the brostallicin chemical structure drives

the DNA interaction towards AT-rich regions in the same way as previously shown for tallimustine. In fact, brostallicin shows a noncovalent DNA interaction effect superimposable to that of

tallimustine and distamycin A (internal positive control). These regions are highlighted by brackets. The differences in band intensities were due to differences in gel loading. On the basis

of the previously reported data showing that brostallicin is able to covalently interact with DNA upon _in vitro_ reduction by the GSH/GST system (Geroni et al, 2002), we further tested

this hypothesis by incubating the drug-DNA solution with and without GSH and GST in an _in vitro_ system. The sequence-specific, covalent DNA interaction of brostallicin in comparison with

tallimustine was analysed by the Taq polymerase stop assay. This assay is a linear amplification method employing the properties of DNA polymerase to investigate the sequence selectivity of

the interaction between DNA-damaging agents and the DNA. As expected, tallimustine retained its high sequence specificity in alkylating DNA at the target hexamer (5′-TTTTGA), while

brostallicin _per se_ was completely unable to produce any alkylation in the selected DNA region (Figure 3). Brostallicin alone did not alkylate DNA, while a band was observed when GST/GSH

was added to the reaction mixture. In the absence of brostallicin, GSH/GST did not induce any alteration able to block Taq polymerase. It is important to underline the fact that, although

the interaction of brostallicin with DNA involves AT-rich regions, the compound binds to a sequence (AAAG) different from those previously reported for tallimustine. Studies are still in

progress to better define the sequence of the alkylated regions. LOSS OF MLH1 OR MSH2 DOES NOT ALTER SENSITIVITY TO BROSTALLICIN The question was addressed as to whether loss of either MLH1

or MSH2 affects the sensitivity to brostallicin using the clonogenic assay. The data presented in Table 1 show that MLH1-deficient HCT116 cells are nearly as sensitive as MLH1-proficient

HCT116+ch3 cells to this drug (_P_=0.36). This indicates that MLH1 is not involved in brostallicin-mediated cytotoxicity. Furthermore, MSH2-deficient HEC59 cells are as sensitive to

brostallicin as MSH2-proficient HEC59+ch2 cells (_P_=0.41), indicating that brostallicin-mediated cytotoxicity does not require functional MSH2. Brostallicin cytotoxiciy has been compared to

tallimustine. The results show that MLH1-deficient and MSH2-deficient cells are three-fold (_P_<0.01) and 1.8-fold (_P_=0.03), respectively, less sensitive to tallimustine than their

respective proficient counterparts. SENSITIVITY TO BROSTALLICIN, BUT NOT TO TALLIMUSTINE, IS RETAINED AFTER LOSS OF PMS2 Although less frequently mutated than MLH1 or MSH2 in human cancers,

PMS2 may nevertheless be relevant in this respect since it forms a heterodimer with MLH1 and the lack of one or the other partner affects MMR activity. Based on the model that cytotoxicity

of tallimustine, but not the _α_-bromoacrylic derivatives, is dependent on functional MMR, it is anticipated that loss of PMS2 negatively affects sensitivity to tallimustine, but not to

brostallicin. The effect of loss of PMS2 on drug sensitivity was investigated in p53-deficient cells derived from knockout mice. Table 2 shows that the clonogenic survival after treatment

with brostallicin in PMS2-deficient cells was not different from that in PMS2-proficient cells (_P_=0.79). In contrast, PMS2-deficient cells were 1.6-fold less sensitive to tallimustine than

PMS2-proficient cells (_P_=0.02). Thus, PMS2-deficient p53-null mouse fibroblasts retain sensitivity to brostallicin. The 1.6-fold resistance to tallimustine in PMS2-deficient cells

indicates a role for PMS2 in sensitivity to this compound. LOSS OF ATM OR DNA-PK DOES NOT AFFECT SENSITIVITY TO BROSTALLICIN It has previously been proposed that the cytotoxic effect of the

_α_-bromoacrylic derivative PNU-151807 interferes with the cell cycle checkpoint control (Marchini et al, 1999). Although yet unknown, a possible pathway may include ATM or DNA-PK, members

of the PI3-like kinase family, which are important kinases for connecting DNA damage monitoring and cellular responses such as cell cycle checkpoint activation and apoptosis. The question

was addressed as to whether the sensitivity to brostallicin is affected by loss of ATM or DNA-PK in a p53-deficient genetic background. We used embryonic fibroblasts from knockout mice. The

data presented in Figure 4 show that ATM-deficient cells (0.8±0.3 _μ_ M) were as sensitive to brostallicin as ATM-proficient cells (0.9±0.2 _μ_ M) in a p53-deficient genetic setting

(_P_=0.60). Likewise, DNA-PK-deficient cells (17.5±0.7 nM) were as sensitive to brostallicin as DNA-PK-proficient cells (21.0±1.4 nM) in a p53-null background (_P_=0.13). Thus, neither ATM

nor DNA-PK seems to be involved in the sensitivity to brostallicin in p53-deficient mouse cells. DISCUSSION The present study demonstrates that brostallicin, a novel _α_-bromoacrylic,

second-generation DNA MGB structurally related to distamycin A, maintains its cytotoxic effect in cells deficient for the MMR proteins MLH1, MSH2, or PMS2. The data permit drawing several

conclusions. First, brostallicin, the lead compound of a novel class of MGBs in clinical trials, exerts its cytotoxic effect regardless of the MMR status, suggesting that further clinical

testing of brostallicin in tumours deficient in MMR is to be recommended. Second, brostallicin-induced cytotoxicity can occur in the absence of functional ATM or DNA-PK in p53-deficient

cells, indicating that brostallicin-induced cytotoxicity in this setting is independent of PI3-like kinase family status. Third, brostallicin is the first MGB unable to _per se_ covalently

interact with DNA. It requires the GSH/GST system to alkylate DNA with a sequence specificity different from that reported for previously tested alkylating molecules. MMR plays an important

role in the correction of spontaneously occurring errors during DNA processing that have escaped the DNA polymerase proof-reading activity, thereby preserving the integrity of the genome by

preventing the occurrence of gene mutations and tumorigenesis (Modrich, 1991). Spontaneous tumours arising from MMR deficiency include the hereditary nonpolyposis colon cancer as well as

some sporadic carcinomas such as mammary, ovarian, or endometrial cancers (Peltomaki, 2001). MMR monitors specific types of DNA damage introduced by DNA-damaging agents, and subsequently

triggers an apoptotic response (Fink et al, 1998). Loss of MMR hence results in resistance to a variety of widely used anticancer drugs, including the topoisomerase I poisons camptothecin

and topotecan, the topoisomerase II poisons doxorubicin, epirubicin, mitoxantrone and etoposide, and some platinum compounds such as cisplatin and carboplatin, as well as some alkylating

agents including MNNG and busulphan (Branch et al, 1995; Drummond et al, 1996; Fink et al, 1998, 1996; Fedier et al, 2001). Interestingly, the MMR status also affects the activity of several

MGBs such as CC-1065 analogues and the distamycin-derivative tallimustine, but not that of the _α_-bromoacryoyl derivative of distamycin A (PNU-151807) (Colella et al, 1999). The present

study expands on this previous finding by demonstrating that brostallicin, a novel second-generation DNA MGB structurally related to PNU-151807, exerts its cytotoxic effect regardless of the

MMR status. Brostallicin as well as the class of the taxanes (Fedier et al, 2001) and photodynamic therapy (Schwarz et al, 2002) may thus represent valuable options for the treatment of

tumours disabled in MMR. The _α_-bromoacryoyl moiety has been proposed to be important since it reacts with GSH, and reactive drug-GSH intermediates may then modify the DNA by mechanisms not

yet fully understood (Geroni et al, 2002; Cozzi, 2003). DNA interaction data reported in the present study suggest that the distamycin A backbone drives the brostallicin molecule towards

the AT regions present in the minor groove of the DNA. In addition, brostallicin binds covalently to DNA through interaction with the GSH/GST system. Brostallicin covalently binds to DNA

with a completely different sequence specificity than tallimustine. One hypothesis for the different behaviour of brostallicin against MMR status is that this covalent interaction is not

substrate for MMR, whereas the alkylated DNA by tallimustine is recognised by MMR. It should be noted that no direct interaction between MMR and the GSH/GST system is known, and that the

GSH/GST status of the cell lines under study does not matter for the experiments because the cell lines are quasi-isogenic, that is, they differ only in their MMR status and the extra

chromosomes. Moreover, as reported for PNU-151807, the bromoacryloyl moiety seems to be relevant for cell cycle checkpoint control (Marchini et al, 1999). The identity of mediators for

signalling between DNA damage and downstream effectors is not clear. One possibility is that the DNA damage is recognised by one or several members of BASC (BRCA1-associated genome

surveillance complex), a multiprotein complex including BRCA1, ATM, MMR proteins, and other proteins implicated in DNA repair (Wang et al, 2000). Our data, however, show that deficiency in

ATM or DNA-PK did not affect brostallicin sensitivity in p53-deficient cells, arguing against a role of these kinases in these cells. Since these kinases are activated upon DNA double-strand

breaks introduced by radiation or radiomimetic drugs (Jackson, 1997; Smith et al, 1999), _α_-bromoacryoyl derivatives seem unlikely to produce this type of lesion. Although the cytotoxic

effect of tallimustine and PNU-151807 has been shown not to be dependent on the p53 status (Marchini et al, 1999), the data for these kinases obtained in p53-deficient cells may not be

conclusive for p53-proficient cells. There is an apparent higher sensitivity to brostallicin of the DNA-PK data set compared to the ATM data set, but this is likely due to the use of two

assays that differ in their sensitivities. Mutations in the p53 tumour suppressor gene are found in a large fraction of human cancers (Hollstein et al, 1991) and this may be the genetic

basis underlying failure to respond to chemotherapy (Ferreira et al, 1999). PNU-151807 has recently been reported to retain sensitivity against cells disabled in p53 function (Marchini et

al, 1999), indicating that PNU-151807-mediated cytotoxicity does not require functional p53. We have recently shown that additional loss of PMS2 in p53-deficient cells increases cytotoxicity

to a variety of anticancer agents (Fedier et al, 2002). This hypersensitising effect, however, was not observed in response to treatment with brostallicin. For tallimustine, even an

opposite effect was observed in PMS2-deficient cells, suggesting that tallimustine-induced DNA damage is a substrate for MMR in p53-deficient cells. Consistent with this,

tallimustine-induced DNA damage has already been shown to be a substrate for MMR in p53-proficient cells (Colella et al, 1999). We also observed that tallimustine is less toxic than

brostallicin in p53-deficient cells and that this effect is much greater than the difference in sensitivity to tallimustine between MMR-deficient and -proficient cells. This marked effect

was not observed in p53-proficient cells. As the status of p53 has been reported not to markedly affect the sensitivity of human tumour cells to either tallimustine or PNU-151807 (Marchini

et al, 1998), this effect in p53-deficient cells may be ascribed to the mouse origin and/or to the fibroblast cell type. In summary, the present study demonstrates that brostallicin-mediated

cytotoxicity does not depend on the MMR status of tumour cells, and that, at least in p53-deficient mouse cells, functional ATM or DNA-PK is not required. Brostallicin potentially offers

the advantage of having efficacy on MMR-defective tumours that are refractory to several anticancer agents. Since the responsiveness to cisplatin treatment is affected by both MMR status and

GSH/GST level/expression, brostallicin is a good candidate for clinical protocols. CHANGE HISTORY * _ 16 NOVEMBER 2011 This paper was modified 12 months after initial publication to switch

to Creative Commons licence terms, as noted at publication _ REFERENCES * Bailey SM, Meyne J, Chen DJ, Kurimasa A, Li GC, Lehnert BE, Goodwin EH (1999) DNA double-strand break repair

proteins are required to cap the ends of mammalian chromosomes. _Proc Natl Acad Sci USA_ 96: 14899–14904 Article  CAS  PubMed  PubMed Central  Google Scholar  * Boyer JC, Umar A, Risinger

JI, Lipford JR, Kane M, Yin S, Barrett JC, Kolodner RD, Kunkel TA (1995) Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. _Cancer Res_

55: 6063–6070 CAS  PubMed  Google Scholar  * Branch P, Hampson R, Karran P (1995) DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma

cell lines. _Cancer Res_ 55: 2304–2309 CAS  PubMed  Google Scholar  * Broggini M, Coley HM, Mongelli N, Pesenti E, Wyatt MD, Hartley JA, D'Incalci M (1995) DNA sequence-specific adenine

alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. _Nucleic Acids Res_ 23: 81–87 Article  CAS  PubMed  PubMed Central 

Google Scholar  * Broggini M, Erba E, Ponti M, Ballinari D, Geroni C, Spreafico F, D'Incalci M (1991) Selective DNA interaction of the novel distamycin derivative FCE 24517. _Cancer

Res_ 51: 199–204 CAS  PubMed  Google Scholar  * Colella G, Marchini S, D'Incalci M, Brown R, Broggini M (1999) Mismatch repair deficiency is associated with resistance to DNA minor

groove alkylating agents. _Br J Cancer_ 80: 338–343 Article  CAS  PubMed  PubMed Central  Google Scholar  * Cozzi P (2000) Recent outcome in the field of distamycin-derived minor groove

binders. _Farmaco_ 55: 168–173 Article  CAS  PubMed  Google Scholar  * Cozzi P (2003) The discovery of a new potential anticancer drug: a case history. _Farmaco_ 58: 213–220 Article  CAS 

PubMed  Google Scholar  * D'Alessio R, Geroni C, Biasoli G, Pesenti E, Grandi M, Mongelli N (1994) Structure–activity relationship of novel distamycin A derivatives: synthesis and

antitumor activity. _Bioorganic Med Chem Lett_ 4: 1467–1472 Article  CAS  Google Scholar  * D'Incalci M (1994) DNA-minor groove alkylators, a new class of anticancer agents. _Ann Oncol_

5: 877–878 Article  CAS  PubMed  Google Scholar  * Drummond JT, Anthoney DA, Brown R, Modrich P (1996) Cisplatin and adriamycin resistance are associated with MutL_α_ and mismatch repair

deficiency in an ovarian tumor cell line. _J Biol Chem_ 271: 19645–19648 Article  CAS  PubMed  Google Scholar  * Fedier A, Ruefenacht UB, Schwarz VA, Haller U, Fink D (2002) Increased

sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2. _Br J Cancer_ 87: 1027–1033 Article  CAS  PubMed  PubMed Central  Google Scholar  * Fedier A, Schwarz VA, Walt H,

Delli Carpini R, Haller U, Fink D (2001) Resistance to topoisomerase poisons due to loss of DNA mismatch repair. _Int J Cancer_ 93: 571–576 Article  PubMed  Google Scholar  * Ferreira CG,

Tolis C, Giaccone G (1999) p53 and chemosensitivity. _Ann Oncol_ 10: 1011–1021 Article  CAS  PubMed  Google Scholar  * Fink D, Aebi S, Howell SB (1998) The role of DNA mismatch repair in

drug resistance. _Clin Cancer Res_ 4: 1–6 CAS  PubMed  Google Scholar  * Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, Howell SB (1996) The role of DNA mismatch repair in

platinum drug resistance. _Cancer Res_ 56: 4881–4886 CAS  PubMed  Google Scholar  * Geroni C, Marchini S, Cozzi P, Galliera E, Ragg E, Colombo T, Battaglia R, Howard M, D'Incalci M,

Broggini M (2002) Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to gluthathione. _Cancer Res_ 62: 2332–2336 CAS  PubMed  Google Scholar  * Hartley JA, Lown

JW, Mattes WB, Kohn KW (1988) DNA sequence specificity of antitumor agents. Oncogenes as possible targets for cancer therapy. _Acta Oncol_ 27: 503–510 Article  CAS  PubMed  Google Scholar  *

Hertzberg RP, Dervan PB (1984) Cleavage of DNA with methidiumpropyl-EDTA-iron(II): reaction conditions and product analyses. _Biochemistry_ 14: 3934–3945 Article  Google Scholar  *

Hollstein M, Sidransky B, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. _Science_ 253: 49–53 Article  CAS  PubMed  Google Scholar  * Hurley LH, Reynolds VL, Swenson DH,

Petzold GL, Scahill TA (1984) Reaction of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with sequence specificity. _Science_ 226: 843–844 Article  CAS  PubMed  Google

Scholar  * Jackson SP (1997) DNA-dependent protein kinase. _Int J Biochem Cell Biol_ 29: 935–938 Article  CAS  PubMed  Google Scholar  * Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM,

Kunkel TA, Boland CR (1994) Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces _N_-methyl-_N_′-nitro-_N_-nitrosoguanidine tolerance in colon

tumor cells with homozygous hMLH1 mutation. _Cancer Res_ 54: 4308–4312 CAS  PubMed  Google Scholar  * Lee M, Rhodens VL, Wyatt MD, Forrow S, Hartley JA (1993) Design, synthesis, and

biological evaluation of DNA sequence and minor groove selective alkylating agents. _Anticancer Drug Des_ 8: 173–193 CAS  PubMed  Google Scholar  * Li LH, Dekonong TF, Kelly RC, Krueger WC,

McGovren JP, Padbury GE, Petzold GL, Wallace TL, Ouding RJ, Prairie MD, Gebhard I (1992) Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue.

_Cancer Res_ 52: 4904–4913 CAS  PubMed  Google Scholar  * Li LH, Swenson D, Schpock S, Kuentzel S, Dayton B, Kreiger W (1982) CC-1065 (NSC-298223) a novel antitumor agent that interacts

strongly with double-strand DNA. _Cancer Res_ 42: 999–1104 CAS  PubMed  Google Scholar  * Marchini S, Ciro M, Gallinari F, Cozzi P, D'Incalci M, Broggini M (1999) Bromoacryloyl

derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity. _Br J Cancer_ 80: 991–997 Article  CAS  PubMed  PubMed Central  Google

Scholar  * Marchini S, Cozzi P, Beria I, Geroni C, Capolongo L, D'Incalci M, Broggini M (1998) Sequence specific alkylation of novel tallimustine derivatives. _Anticancer Drug Design_

13: 193–205 CAS  Google Scholar  * Martin DG, Biles C, Gerpheide SA, Hanka LJ, Krueger WC, McGovren JP, Mizsak SA, Neil GL, Stewart JC, Visser J (1981) CC-1065 (NSC 298223), a potent new

antitumor agent improved production and isolation, characterization and antitumor activity. _J Antibiot Tokyo_ 34: 1119–1125 Article  CAS  PubMed  Google Scholar  * Modrich P (1991)

Mechanisms and biological effects of DNA mismatch repair. _Ann Rev Genet_ 25: 229–253 Article  CAS  PubMed  Google Scholar  * Mosmann T (1983) Rapid colorimetric assay for cellular growth

and survival: application to proliferation and cytotoxicity assays. _J Immunol Methods_ 65: 55–63 Article  CAS  PubMed  Google Scholar  * Peltomaki P (2001) DNA mismatch repair and cancer.

_Mutat Res_ 488: 77–85 Article  CAS  PubMed  Google Scholar  * Ponti M, Forrow SM, Souhami RL, D'Incalci M, Hartley JA (1991) Measurement of the sequence specificity of covalent DNA

modification by antineoplastic agents using Taq DNA polymerase. _Nucleic Acids Res_ 19: 2929–2933 Article  CAS  PubMed  PubMed Central  Google Scholar  * Reynolds VL, Molineux IJ, Kaplan DJ,

Swenson DH, Hurley LH (1985) Reaction of the antitumor antibiotic CC-1065 with DNA. Location of the site of thermally induced strand breakage and analysis of DNA sequence specificity.

_Biochemistry_ 24: 6228–6237 Article  CAS  PubMed  Google Scholar  * Schwarz VA, Hornung R, Fedier A, Walt H, Haller U, Fink D (2002) Photodynamic therapy of DNA mismatch repair-deficient

and -proficient tumour cells. _Br J Cancer_ 86: 1130–1135 Article  CAS  PubMed  PubMed Central  Google Scholar  * Smith GC, Cary RB, Lakin ND, Hann BC, Teo SH, Chen DJ, Jackson SP (1999)

Purification and DNA binding properties of the ataxia-telangiectasia gene product ATM. _Proc Natl Acad Sci USA_ 96: 11134–11139 Article  CAS  PubMed  PubMed Central  Google Scholar  * Sun D,

Hurley LH (1992) Effect of the (+)-CC1065-(N3-adenine) DNA adduct on _in vitro_ DNA synthesis mediated by _Escherichia coli_ DNA polymerase. _Biochemistry_ 31: 2822–2829 Article  CAS 

PubMed  Google Scholar  * Umar A, Koi M, Risinger JI, Glaab WE, Tindall KR, Kolodner RD, Boland CR, Barrett JC, Kunkel TA (1997) Correction of hypermutability,

_N_-methyl-_N_′-nitro-_N_-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. _Cancer Res_ 57:

3949–3955 CAS  PubMed  Google Scholar  * Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J (2000) BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair

of aberrant DNA structures. _Genes Dev_ 14: 927–939 CAS  PubMed  PubMed Central  Google Scholar  * Westphal CH, Schmaltz C, Rowan S, Elson A, Fisher DE, Leder P (1997) Genetic interactions

between ATM and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints. _Cancer Res_ 57: 1664–1667 CAS  PubMed  Google Scholar  * Zeng M, Narayanan L, Xu XS,

Prolla TA, Liskay MR, Glazer PM (2000) Ionizing radiation-induced apoptosis via separate pms2- and p53-dependent pathways. _Cancer Res_ 60: 4889–4893 CAS  PubMed  Google Scholar  Download

references ACKNOWLEDGEMENTS We are grateful to Dres M Koi (Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA), P

Glazer (Yale University School of Medicine, New Haven, CT, USA), E Goodwin (Bioscience Division, Los Alamos National Laboratory, Los Alamos, NM, USA), and P Leder (Department of Genetics and

Howard Hughes Medical Institute, Harvard Medical School, Boston, MA, USA) for generously providing the cell lines. This work has been sponsored by the Cancer League of Canton Zurich and by

an unrestricted grant from Pharmacia AG Switzerland (Dübendorf, Switzerland). AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Obstetrics and Gynaecology, Division of Gynaecology,

University Hospital of Zurich, CH-8091, Switzerland A Fedier, U Haller & D Fink * Pharmacia Italy, Oncology, Nerviano, Italy C Fowst, J Tursi & C Geroni * Istituto di Ricerche

Farmacologiche Mario Negri, Milano, Italy S Marchini Authors * A Fedier View author publications You can also search for this author inPubMed Google Scholar * C Fowst View author

publications You can also search for this author inPubMed Google Scholar * J Tursi View author publications You can also search for this author inPubMed Google Scholar * C Geroni View author

publications You can also search for this author inPubMed Google Scholar * U Haller View author publications You can also search for this author inPubMed Google Scholar * S Marchini View

author publications You can also search for this author inPubMed Google Scholar * D Fink View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING

AUTHOR Correspondence to D Fink. RIGHTS AND PERMISSIONS From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share

Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Fedier, A.,

Fowst, C., Tursi, J. _et al._ Brostallicin (PNU-166196) – a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells. _Br J Cancer_ 89, 1559–1565

(2003). https://doi.org/10.1038/sj.bjc.6601316 Download citation * Received: 03 April 2003 * Revised: 08 August 2003 * Accepted: 21 August 2003 * Published: 14 October 2003 * Issue Date: 20

October 2003 * DOI: https://doi.org/10.1038/sj.bjc.6601316 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a

shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * brostallicin * DNA mismatch

repair * drug sensitivity * DNA minor groove binder